A recent coroner’s report has raised serious concerns regarding the use of Candesartan, a medication commonly prescribed for migraines, during pregnancy. This warning follows the heart-wrenching case of Avery Hall, who tragically passed away just four days after birth, highlighting the potential hazards associated with this drug in expecting mothers.
The Circumstances Surrounding Avery’s Death
On 13th November 2024, baby Avery Hall was born in Sunderland but sadly succumbed to complications that included lung damage, low oxygen levels, and impaired blood circulation. These complications are known to be associated with the use of Candesartan during pregnancy, particularly in the later trimesters. The infant’s development was severely affected by reduced amniotic fluid, which hindered both lung growth and kidney function.
Avery’s mother had been prescribed Candesartan, a medication that helps to relax blood vessels, prior to her pregnancy to manage her recurring migraines. However, when she discovered she was expecting in April 2024, she received vague and inconsistent advice from healthcare professionals regarding the continuation of her medication. This lack of clear guidance ultimately led to the tragic outcome.
Inadequate Guidance from Healthcare Professionals
David Place, the Senior Coroner for the City of Sunderland, conducted an investigation into Avery’s death and issued a report urging the need for improved communication and guidance regarding the use of Candesartan among pregnant women. He noted that the mother had been unaware of the risks associated with continuing the medication throughout her pregnancy due to a combination of unclear advice and a lack of follow-up from her antenatal care providers.
Initially prescribed Candesartan 4mg by her GP shortly before her 22nd birthday, the mother was placed on a repeat prescription without being informed of the potential dangers to fetal development should she become pregnant. The National Institute for Health and Care Excellence (NICE) has established guidelines warning against the use of this medication during pregnancy due to its adverse effects.
Despite her inquiries to her GP about which medications were safe to take during her pregnancy, the coroner highlighted that Avery’s mother was not specifically advised to discontinue Candesartan. Instead, a repeat prescription was issued, allowing the medication to be dispensed until just 12 days before Avery’s birth.
The Need for Systematic Changes
Mr Place emphasised the necessity for systemic changes within the healthcare framework to prevent similar tragedies in the future. He pointed out that there were no warning alerts in the prescription system to inform clinicians of the patient’s pregnancy status, which should have prompted a thorough review of her medication.
“Despite the GP’s general advice to stop all medications during pregnancy, Candesartan continued to be prescribed without any clear warnings or checks in place,” Mr Place remarked. This oversight not only contributed to the unfortunate loss of Avery Hall but also raises concerns about the safety protocols in place for pregnant patients taking potentially harmful medications.
Why it Matters
The tragic case of baby Avery underscores the critical importance of clear communication and guidance between healthcare providers and pregnant patients regarding medication safety. As the healthcare community reflects on this heart-wrenching incident, it is pivotal to instigate robust changes that ensure expectant mothers receive accurate information about the risks associated with their medications. This will not only protect future pregnancies but also foster a healthcare environment where patients feel empowered to make informed decisions about their health and that of their unborn children.